Hello, everyone, and how are you today? Cloudy skies are hovering this morning over the Pharmalot campus, where things have settled down now that the short person has left for summer employment and the official mascot has assumed his formal snoozing position. As for us, we are dutifully concocting a few needed cups of stimulation as we dig in for another busy day. No doubt, you can relate. So time to get cracking. As always, we have assembled some items of interest. So hoist your own cup to a successful day and drop us a line when something interesting arises. …
One of the most serious but largely unrecognized problems facing a global immunization effort as it tries to recover from months of missteps and disappointments is difficulty getting doses from airport tarmacs into people’s arms, The New York Times explains. A World Health Organization program known as Covax was supposed to be a global powerhouse, a multibillion-dollar alliance of international health bodies and nonprofits that would use buying power to ensure low-income countries received vaccines as quickly as the rich. Instead, Covax has struggled to acquire doses: It stands half a billion short of its goal. And low-income countries are dangerously unprotected as the Delta variant runs rampant.
Sanofi (SNY) will spend $3.2 billion to purchase Translate Bio (TBIO), its partner in an effort to create an mRNA-based Covid-19 vaccine, STAT writes. The deal follows an announcement in June that the company will create an mRNA vaccines center of excellence, funded with almost $500 million annually, with a goal of creating six experimental vaccine candidates by 2025. Other large drug makers are making similar bets. Pfizer (PFE) has touted its pipeline of potential mRNA vaccines, and GlaxoSmithKline (GSK) has 200 scientists working on mRNA.
Create a display name to comment
This name will appear with your comment